Drug Trial Radar · NCT01883505
A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease Patients
Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jan 6, 2014
Primary completion
Apr 26, 2015
Study completion Apr 26, 2015
Sponsor
- Lead sponsor
- NeuroDerm Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 21, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, placebo-controlled, double-blind, 2-period study evaluating the safety and pharmacokinetics (PK) of ND0612 in Parkinson's disease (PD) patients on an optimized oral levodopa (LD) regimen and experiencing ≥2 h/day of OFF time. Safety and tolerability, PK profile, pump usability, and the potential clinical effect of ND0612 will be explored in subjects with PD and motor fluctuations.
Conditions
- Parkinson's Disease
Interventions
ND0612Drug
Subcutaneous infusion via CRONO ND pump
PlaceboDrug
Subcutaneous infusion via CRONO ND pump
EntacaponeDrug
200 mg oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Dermal Rating Score: Draize ScoreTime frame: 14 days (Period 1)
- Maximum Dermal Rating Score: Erythema and Eschar FormationTime frame: 14 days (Period 1)
- Maximum Dermal Rating Score: EdemaTime frame: 14 days (Period 1)
- Maximum Dermal Rating Score: Presence of NodulesTime frame: 14 days (Period 1)
- Maximum Dermal Rating Score: PruritusTime frame: 14 days (Period 1)
- Maximum Dermal Rating Score: StainingTime frame: 14 days (Period 1)
- Maximum Dermal Rating Score: PainTime frame: 14 days (Period 1)
- Total Oral LD DoseTime frame: Day 15 (Period 1) and Day 22 (Period 2)
- LD CminTime frame: Day 15 (Period 1) and Day 22 (Period 2)
- LD CmaxTime frame: Day 15 (Period 1) and Day 22 (Period 2)
- LD AUC (0-10h)Time frame: Day 15 (Period 1) and Day 22 (Period 2)
- Time LD Concentration >1000 ng/mLTime frame: Day 15 (Period 1) and Day 22 (Period 2)
- LD Concentration FITime frame: Day 15 (Period 1) and Day 22 (Period 2)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Hadassah Medical Center
Jerusalem, Israel
Rabin Medical Center
Petah Tikva, Israel
Tel Aviv Medical Center
Tel Aviv, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.